Erythropoietin-mediated activation of functional properties of peripheral blood mononuclear cells in patients with chronic heart failure



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Stem cell therapy of diseases of the cardiovascular system, such as myocardial infarction is a prospective method for the stimulation of ischemic tissue repair. The main mechanisms of stem and progenitor cells action is a paracrine. The purpose of the study was to assess the effects of erythropoietin on the functional activity of mononuclear cells (MNCs) in patients with chronic heart failure before and after enrichment of peripheral blood with stem and progenitor cells mobilized by granulocyte colony-stimulating factor (G-CSF). 48 patients with coronary heart disease participated in the study. MNCs from the separated blood were isolated by density gradient on Ficoll/verografin. The phenotype of endothelial progenitor cells was investigated using monoclonal antibodies to CD34, CD133, VEGFR2, CD31. The Change of MNCs proliferative potential in response to erythropoietin was evaluated by MTT-test. The cytokine production in conditioned media was studied using ELISA. The effectiveness of mobilized MNC intramyocardial administration was assessed at 6 and 12 months by detection of a change in functional class according to NYHA heart failure, volume ejection fraction of the left ventricle of the heart and a change in myocardial perfusion. We showed that the enrichment of peripheral blood by mobilization of stem and progenitor cells in patients with chronic heart failure led to activation of proliferative potential of MNCs and increased erythropoietin production, a cytokine with pro-angiogenic activity. MNC enriched with stem and progenitor cells being culturing with erythropoietin increased the levels of TNF-α, IL-10, IL-18, IL-8, G-CSF and VEGF, as compared with the basal level of production. Circulating endothelial progenitor cells with the phenotype CD34- /VEGFR2+ have a correlation with the level of erythropoietin production. Secretory erythropoietin level directly correlated with myocardial perfusion, left ventricular ejection fraction and heart failure class at 6 and 12 months follow-up. The findings suggest that erythropoietin improves functional properties of the MNC of patients with heart failure after mobilization with G-CSF.

Full Text

Restricted Access

About the authors

O. V Poveshchenko

Scientific Institute of Clinical and Experimental Lymphology; Novosibirsk Scientific Institute of Circulating Pathology

Email: poveschenkoov@yandex.ru

N. A Bondarenko

Scientific Institute of Clinical and Experimental Lymphology; Novosibirsk Scientific Institute of Circulating Pathology

I. I Kim

Scientific Institute of Clinical and Experimental Lymphology; Novosibirsk Scientific Institute of Circulating Pathology

A. P Lykov

Scientific Institute of Clinical and Experimental Lymphology; Novosibirsk Scientific Institute of Circulating Pathology

M. A Surovtseva

Scientific Institute of Clinical and Experimental Lymphology; Novosibirsk Scientific Institute of Circulating Pathology

E. A Pokushalov

Novosibirsk Scientific Institute of Circulating Pathology

A. B Romanov

Novosibirsk Scientific Institute of Circulating Pathology

A. F Poveshchenko

Scientific Institute of Clinical and Experimental Lymphology; Novosibirsk Scientific Institute of Circulating Pathology

V. I Konenkov

Scientific Institute of Clinical and Experimental Lymphology; Novosibirsk Scientific Institute of Circulating Pathology

A. M Karaskov

Novosibirsk Scientific Institute of Circulating Pathology

References

  1. Zamilpa R., Navarro M.M., Flores I. et al. Stem cell mechanisms during left ventricular remodeling post-myocardial infarction: Repair and regeneration. World J. Cardiol. 2014; 6(7): 610-20.
  2. Hosing C. Hematopoietic stem cell mobilization with G-CSF. Methods Mol. Biol. 2012; 904: 37-47.
  3. Clifford D.M., Fisher S.A., Brunskill S.J. et al. Long-term effects of autologous bone marrow stem cell treatment in acute myocardial infarction: factors that may influence outcomes. Plos One 2012; 7: e37373.
  4. Lai W.H., Ho J.C.Y., Chan Y.C. et al. Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. Plos One 2013; 8(3): e57876.
  5. Gnecchi M., Zhang Z., Ni A. et al. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res. 2008; 103(11): 1204-19.
  6. Crisostomo P.R., Markel T.A., Wang Y. et al. Surgically relevant aspects of stem cell paracrine effects. Surgery 2008; 143: 577-81.
  7. Pagonopoulou O., Efthimiadou A., Lambropoulou M. et al. Erythropoietin and growth factors exhibit differential angiogenic potential in mouse heart. In Vivo 2008; 22: 587-91.
  8. Takahashi T., Tang T., Lai N.C. et al. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 2006; 114: 388-96.
  9. Calvillo L., Latini R., Kajstura J. et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. PNAS USA 2003; 100(8): 4802-6.
  10. Depping R., Kawakami K., Ocker H. et al. Expression of the erythropoietin receptor in human heart. J. Thorac. Cardiovasc. Surg. 2005; 130(3): 877-8.
  11. Goon P.K., Lip G.Y., Boos C.J. et al. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 2006; 8: 79-88.
  12. Коненков В.И., Повещенко О.В., Ким И.И. и др. Влияние G-CSF на проангиогенные свойства мобилизированных клеток периферической крови у больных с хронической сердечной недостаточностью. Гены и клетки 2011; YIt3): 71-5.
  13. Захаров Ю.М. Цитопротекторные функции эритропоэтина. Клиническая нефрология 2009; 1: 16-21.
  14. Kang Y.J., Digicaylioglu M., Russo R. et al. Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders. Ann. Neurol. 2010; 68(3): 342-52.
  15. Liu N.M., Tian J., Wang W.W. et al. Effect of erythropoietin on mesenchymal stem cell differentiation and secretion in vitro in an acute kidney injury microenvironment. Genet. Mol. Res. 2013; 12(4): 6477-87.
  16. Wang P.R. Mouse adult renal progenitor cells in combination with erythropoietin or suramin - a potential new strategy for the treatment of acute kidney injury. Stem Cell Res. Ther. 2013; 4(4): 89.
  17. Ercan E., Bagla A.G., Aksoy A. et al. In vitro protection of adipose tissue-derived mesenchymal stem cells by erythropoietin. Acta Histochem. 2014; 116(1): 117-25.
  18. Santoso T., Irawan C., Alwi I. et al. Safety and feasibility of combined granulocyte colony stimulating factor and erythropoetin based-stem cell therapy using intracoronary infusion of peripheral blood stem cells in patients with recent anterior myocardial infarction: one-year follow-up of a phase 1 study. Acta Med. Indones. 2011; 43(2): 112-21.
  19. Tousoulis D., Vogiatzi G., Briasoulis A. et al. Effects of intramuscular administration of hematopoietic progenitor and coadministration oferythropoietin on blood perfusion, angiogenic factors and vascularization in a murine model of limb ischemia. Int. J. Cardiol. 2013; 169(3): 229-31.
  20. Pellegrini L., Bennis Y., Guillet B. et al. Therapeutic benefit of a combined strategy using erythropoietin and endothelial progenitor cells after transient focal cerebral ischemia in rats. Neurol. Res. 2013; 35(9): 937-47.
  21. Bennis Y., Sarlon-Bartoli G., Guillet B. et al. Priming of late endothelial progenitor cells with erythropoietin before transplantation requires the CD131 receptor subunit and enhances their angiogenic potential. J. Thromb. Haemost. 2012; 10(9): 1914-28.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies